These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24722807)

  • 1. Optical coherence tomography imaging of everolimus-eluting bioresorbable vascular scaffold implanted into coronary vein graft at 3-month follow-up.
    Roleder T; Parma Z; Smolka G; Ochała A; Wojakowski W
    Eur Heart J; 2014 Sep; 35(33):2207. PubMed ID: 24722807
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
    Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optical coherence tomography follow-up after bioresorbable in metallic and metallic in bioresorbable stenting: tackling in-stent restenosis in the era of bioresorbable vascular scaffolds.
    Frangieh AH; Templin C; Binder RK
    Eur Heart J; 2015 Aug; 36(32):2183. PubMed ID: 26040803
    [No Abstract]   [Full Text] [Related]  

  • 4. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry.
    La Manna A; Miccichè E; D'Agosta G; Tensol Rodrigues Pereira G; Attizzani GF; Capranzano P; Capodanno D; Tamburino C
    Int J Cardiol; 2018 Feb; 253():45-49. PubMed ID: 29137819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
    J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion.
    Wiebe J; Liebetrau C; Dörr O; Most A; Weipert K; Rixe J; Bauer T; Möllmann H; Elsässer A; Hamm CW; Nef HM
    Int J Cardiol; 2015 Jan; 179():90-4. PubMed ID: 25464422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
    Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-human description of everolimus-eluting bioabsorbable vascular scaffold implantation for the treatment of drug-eluting stent failure: insights from optical coherence tomography.
    Grasso C; Attizzani GF; Patané M; Ohno Y; Capodanno D; Tamburino C
    Int J Cardiol; 2013 Oct; 168(4):4490-1. PubMed ID: 23890924
    [No Abstract]   [Full Text] [Related]  

  • 10. Culotte Technique With a Bioresorbable Vascular Scaffold: 12 Months' Follow-up.
    Vera Pernasetti L; Gutiérrez H; Ramos B
    Rev Esp Cardiol (Engl Ed); 2016 Oct; 69(10):973-974. PubMed ID: 27085839
    [No Abstract]   [Full Text] [Related]  

  • 11. Side branch occlusion after bioresorbable vascular scaffold implantation: lessons from optimal coherence tomography.
    Sato K; Panoulas VF; Kawamoto H; Naganuma T; Miyazaki T; Latib A; Colombo A
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):116-8. PubMed ID: 25616826
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year optical coherence tomography follow-up of an everolimus-eluting bioresorbable vascular scaffold: changing the paradigm of coronary stenting?
    Karanasos A; Simsek C; Serruys P; Ligthart J; Witberg K; van Geuns RJ; Sianos G; Zijlstra F; Regar E
    Circulation; 2012 Aug; 126(7):e89-91. PubMed ID: 22891170
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds.
    Gomez-Lara J; Brugaletta S; Diletti R; Garg S; Onuma Y; Gogas BD; van Geuns RJ; Dorange C; Veldhof S; Rapoza R; Whitbourn R; Windecker S; Garcia-Garcia HM; Regar E; Serruys PW
    Eur Heart J; 2011 Feb; 32(3):294-304. PubMed ID: 21123276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioresorbable polymeric vascular scaffolds: a cautionary tale.
    Ormiston JA; De Vroey F; Serruys PW; Webster MW
    Circ Cardiovasc Interv; 2011 Oct; 4(5):535-8. PubMed ID: 22010192
    [No Abstract]   [Full Text] [Related]  

  • 17. 'Full-plastic jacket' with bioresorbable vascular scaffolds: 5-year optical coherence tomography follow-up.
    Nai Fovino L; Barioli A; Tarantini G
    Eur Heart J Cardiovasc Imaging; 2019 Mar; 20(3):370. PubMed ID: 30561565
    [No Abstract]   [Full Text] [Related]  

  • 18. Five-year follow-up of the ABSORB bioresorbable everolimus-eluting vascular scaffold system: multimodality imaging assessment.
    García-García HM; Schultz C; Duckers E; Regar E; Ligthart J; Serruys PW; van Geuns RJ
    EuroIntervention; 2013 Feb; 8(10):1126-7. PubMed ID: 23014900
    [No Abstract]   [Full Text] [Related]  

  • 19. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent.
    Ormiston JA; Webster MW; Armstrong G
    Catheter Cardiovasc Interv; 2007 Jan; 69(1):128-31. PubMed ID: 17139655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioresorbable everolimus-eluting vascular scaffold for the treatment of chronic total occlusions: CTO-ABSORB pilot study.
    Vaquerizo B; Barros A; Pujadas S; Bajo E; Estrada D; Miranda-Guardiola F; Rigla J; Jiménez M; Cinca J; Serra A
    EuroIntervention; 2015 Sep; 11(5):555-63. PubMed ID: 25499833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.